STOCK TITAN

Alimera Sciences, Inc. - $ALIM STOCK NEWS

Welcome to our dedicated page for Alimera Sciences news (Ticker: $ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alimera Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alimera Sciences's position in the market.

Rhea-AI Summary
Alimera Sciences, Inc. announces that clinical data for ILUVIEN® will be featured in three posters and a presentation at the American Academy of Ophthalmology’s 127th Annual Meeting. The data comes from the PALADIN study, which evaluates the long-term safety of ILUVIEN for patients with diabetic macular edema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary
Alimera Sciences reports Q3 2023 financial results, with net revenue up 72% to $23.4 million and net loss decreased by 74% to $1.4 million. Adjusted EBITDA of $5.4 million. Successful integration of YUTIQ into the U.S. segment. Alimera expects over $100 million in net revenue and more than $20 million in Adjusted EBITDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.99%
Tags
-
Rhea-AI Summary
Alimera Sciences announces clinical data for ILUVIEN and YUTIQ will be featured in presentations at Retina Society's Annual Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
none
Rhea-AI Summary
Alimera Sciences appoints Jason Werner as COO and Dr. Philip Ashman as President of International Operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
management
-
Rhea-AI Summary
Alimera Sciences Inc. to present corporate overview at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.03%
Tags
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) will report second quarter financial results on August 10, 2023. A conference call will be held at 9:00 AM ET to review financial results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
none
-
Rhea-AI Summary
Alimera Sciences announces acquisition of additional commercialization rights for YUTIQ and projects significant revenue growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.42%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.42%
Tags
conferences
Alimera Sciences, Inc.

Nasdaq:ALIM

ALIM Rankings

ALIM Stock Data

191.17M
8.06M
8.75%
91.96%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ALPHARETTA

About ALIM

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.